{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-045948","form_type":"8-K","ticker":"ZVSA","cik":"0001859007","company_name":"ZyVersa Therapeutics, Inc.","filed_at":"2023-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.150286+00:00","generated_at":"2026-06-07T08:19:45.025872+00:00","sec_items":["4.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ZyVersa Therapeutics dismisses Ernst & Young, appoints Marcum as auditor","bullets":["Dismissed EY as independent auditor on Dec 22, 2023; EY served from 2019 through Q3 2023 and interim period.","EY's audit reports for FY2022 and FY2021 included going-concern explanatory paragraph about substantial doubt.","No disagreements with EY; material weaknesses in internal controls over complex transactions were disclosed in 2022 10-K.","Audit Committee appointed Marcum LLP as new independent registered public accounting firm for FY2023.","No prior consultations with Marcum regarding accounting principles or audit opinions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-045948","json":"https://secwatch.observer/filing/0001493152-23-045948.json","markdown":"https://secwatch.observer/filing/0001493152-23-045948.md","text":"https://secwatch.observer/filing/0001493152-23-045948.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223045948/0001493152-23-045948-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223045948/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T08:19:45.025872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64cebbf69d70b3f64dc44c4bf11397ac3ffb3aa9","claim":"ZyVersa Therapeutics, Inc. engaged Marcum LLP as its auditor.","evidence_excerpt":"On December 22, 2023, the Audit Committee appointed Marcum as the Company’s new independent registered public accounting firm commencing with the Company’s fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223045948/0001493152-23-045948-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Marcum LLP"}],"fact_type":"auditor_change"},{"claim_id":"aeb0fdd876af70a3ff9e694b4709e4062ecc9169","claim":"ZyVersa Therapeutics, Inc. dismissed Ernst & Young LLP as its auditor.","evidence_excerpt":"dismissed Ernst & Young LLP (\"EY\") as the Company’s independent registered public accounting firm.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223045948/0001493152-23-045948-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"Ernst & Young LLP"},{"label":"Successor","value":"Marcum LLP"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}